András Bikov1, Alpár Horváth2,3, Gábor Tomisa2,3, Liza Bártfai4, Zoltán Bártfai5. 1. Department of Pulmonology, Semmelweis University, 1/C, Diós árok, Budapest, 1125, Hungary. andras.bikov@gmail.com. 2. Chiesi Hungary Ltd., Dunavirág u. 2, Budapest, 1138, Hungary. 3. Department of Pulmonology, University of Debrecen, Nagyerdei körút 98, Debrecen, 4012, Hungary. 4. Sopron Health Centre, Gyori u. 15, Sopron, 9400, Hungary. 5. Pereszteg-Pinnye General Practitioner Praxis, Petofi Sandor u. 29, Pereszteg, 9484, Hungary.
Abstract
PURPOSE: Comorbidities associated with chronic obstructive pulmonary disease (COPD) affect quality of life and increase mortality. Asthma-COPD overlap (ACO) may express a different profile of comorbidities compared to COPD alone. It is unclear how recent changes in GOLD recommendations affect the profile of comorbidities in COPD and ACO. METHODS: Eight hundred and thirty-four patients with COPD were recruited from 67 Hungarian secondary care outpatient clinics, 469 of them had ACO. Comorbidities were defined by respiratory specialists based on medical history, patient report, and medications. COPD grades were defined according to the old 2016 and the new 2017 GOLD document. Comorbidities were compared along COPD ABCD groups determined by the old and new GOLD. RESULTS: 66 and 72% of the COPD patients in groups C and D (GOLD 2016) were recategorized to groups A and B (GOLD 2017), respectively. There was no difference in the prevalence of disorders along the 2016 GOLD categories except for osteoporosis in ACO (p = 0.01). When the patients were categorized according to the 2017 GOLD criteria, the prevalence of osteoporosis (p = 0.01) was different among the four groups in all COPD patients. Subgroup analysis of non-ACO COPD patients revealed inter-group differences for cardiac arrhythmia (p < 0.01). No alteration was seen in the prevalence of coronary artery disease, hypertension, diabetes, or the total number of comorbidities. CONCLUSION: A significant number of patients are recategorized according to the GOLD 2017 criteria. This change only marginally affects the profile of comorbidities; still this needs to be considered when assessing the patients in daily practice.
PURPOSE: Comorbidities associated with chronic obstructive pulmonary disease (COPD) affect quality of life and increase mortality. Asthma-COPD overlap (ACO) may express a different profile of comorbidities compared to COPD alone. It is unclear how recent changes in GOLD recommendations affect the profile of comorbidities in COPD and ACO. METHODS: Eight hundred and thirty-four patients with COPD were recruited from 67 Hungarian secondary care outpatient clinics, 469 of them had ACO. Comorbidities were defined by respiratory specialists based on medical history, patient report, and medications. COPD grades were defined according to the old 2016 and the new 2017 GOLD document. Comorbidities were compared along COPD ABCD groups determined by the old and new GOLD. RESULTS: 66 and 72% of the COPDpatients in groups C and D (GOLD 2016) were recategorized to groups A and B (GOLD 2017), respectively. There was no difference in the prevalence of disorders along the 2016 GOLD categories except for osteoporosis in ACO (p = 0.01). When the patients were categorized according to the 2017 GOLD criteria, the prevalence of osteoporosis (p = 0.01) was different among the four groups in all COPDpatients. Subgroup analysis of non-ACO COPDpatients revealed inter-group differences for cardiac arrhythmia (p < 0.01). No alteration was seen in the prevalence of coronary artery disease, hypertension, diabetes, or the total number of comorbidities. CONCLUSION: A significant number of patients are recategorized according to the GOLD 2017 criteria. This change only marginally affects the profile of comorbidities; still this needs to be considered when assessing the patients in daily practice.
Authors: Roy A Pleasants; Jill A Ohar; Janet B Croft; Yong Liu; Monica Kraft; David M Mannino; James F Donohue; Harry L Herrick Journal: COPD Date: 2013-10-23 Impact factor: 2.409
Authors: Tomas Konecny; Jae Yoon Park; Kiran R Somers; Dana Konecny; Marek Orban; Filip Soucek; Kenneth O Parker; Paul D Scanlon; Samuel J Asirvatham; Peter A Brady; Charanjit S Rihal Journal: Am J Cardiol Date: 2014-05-02 Impact factor: 2.778
Authors: Kathrin Kahnert; Peter Alter; David Young; Tanja Lucke; Joachim Heinrich; Rudolf M Huber; Jürgen Behr; Margarethe Wacker; Frank Biertz; Henrik Watz; Robert Bals; Tobias Welte; Hubert Wirtz; Felix Herth; Jørgen Vestbo; Emiel F Wouters; Claus F Vogelmeier; Rudolf A Jörres Journal: Respir Med Date: 2017-12-05 Impact factor: 3.415
Authors: Alvar Agusti; Lisa D Edwards; Bartolomé Celli; William Macnee; Peter M A Calverley; Hana Müllerova; David A Lomas; Emiel Wouters; Per Bakke; Steve Rennard; Courtney Crim; Bruce E Miller; Harvey O Coxson; Julie C Yates; Ruth Tal-Singer; Jørgen Vestbo Journal: Eur Respir J Date: 2013-06-13 Impact factor: 16.671
Authors: Renáta M Böcskei; Béla Benczúr; György Losonczy; Miklós Illyés; Attila Cziráki; Veronika Müller; Anikó Bohács; András Bikov Journal: Lung Date: 2019-02-28 Impact factor: 2.584
Authors: Sun-Wung Hsieh; Da-Wei Wu; Chih-Wen Wang; Szu-Chia Chen; Chih-Hsing Hung; Chao-Hung Kuo Journal: Int J Environ Res Public Health Date: 2021-02-27 Impact factor: 3.390
Authors: Sheila Sánchez Castillo; Lee Smith; Arturo Díaz Suárez; Guillermo Felipe López Sánchez Journal: Int J Environ Res Public Health Date: 2020-01-16 Impact factor: 3.390